InVitae (NVTA) Misses Q4 EPS by 79c

InVitae (NYSE: NVTA) reported Q4 EPS of ($1.34), $0.79 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $96.8 million versus the consensus estimate of $98.4 million.

GUIDANCE:

InVitae sees FY2021 revenue in excess of $450 million, versus the consensus of $488.4 million.

For earnings history and earnings-related data on InVitae (NVTA) click here.

You May Also Be Interested In

• Nebius soars on second quarter revenue beat
• Medicis Pharmaceutical Corp. (MRX) Tops Q2 EPS by 39c
• WhiteFiber, Inc. (WYFI) Misses Q2 EPS by 36c